English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Monday, January 30, 2023
Lecanemab Receives Priority Review Status in Japan
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において優先審査品目に指定
Friday, January 27, 2023
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency
エーザイとバイオジェン、抗アミロイドβプロトフィブリル抗体「レカネマブ」について早期アルツハイマー病に係る販売承認申請が欧州医薬品庁により受理
Thursday, January 19, 2023
Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
エーザイ、イスラエルの医薬品販売子会社が事業活動を開始
Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
Wednesday, January 18, 2023
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
エーザイ、米国臨床腫瘍学会消化器がんシンポジウム2023において消化器系がんに対する治療薬の最新の開発研究の演題を発表
Monday, January 16, 2023
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Copyright © 2023 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575